Literature DB >> 14714910

The blood-brain barrier in systemic lupus erythematosus.

N J Abbott1, L L F Mendonça, D E M Dolman.   

Abstract

Central nervous system (CNS) involvement may occur in 20-70% of systemic lupus erythematosus (SLE) patients where neurological symptoms are overt; this is termed neuropsychiatric lupus or NPSLE. This review summarizes evidence that damage to the brain endothelium forming the blood-brain barrier (BBB) is a contributory factor in NPSLE. The normal CNS is protected by blood-tissue barriers at three sites, the brain endothelium (BBB), the choroid plexus epithelium (blood-CSF barrier) and the arachnoid epithelium. The tight junctions of the barrier layers severely restrict entry of plasma constituents including proteins, so that the CSF and brain interstitial fluid contain low levels of protein. Methods for diagnosing BBB damage include imaging (CT, MRI) using contrast agents, and analysing protein content and profiles of CSF Changes in the albumin quotient Qalbumin show evidence for barrier damage, while changes in the immunoglobulin (Ig) index can indicate intrathecal antibody production. However, BBB damage may be transient, and hence undetected or underestimated. Few mechanistic studies exist, but the two main candidate mechanisms for BBB damage are microthrombi in cerebral vessels leading to ischaemia, and immune-mediated attack and activation of the endothelium leading to local cytokine production. Both can result in barrier breakdown. Neurological syndromes could then be secondary to damage to the BBB. The implications for treatment of NPSLE are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14714910     DOI: 10.1191/0961203303lu501oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  68 in total

Review 1.  Dynamics of CNS barriers: evolution, differentiation, and modulation.

Authors:  N Joan Abbott
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 2.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 3.  Neuroimmunopathology in a murine model of neuropsychiatric lupus.

Authors:  David A Ballok
Journal:  Brain Res Rev       Date:  2006-12-20

4.  Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations.

Authors:  Mo Yin Mok; Eric Y T Chan; Woon Sing Wong; Chak Sing Lau
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

5.  Neuropsychiatric systemic lupus erythematosus reconsidered.

Authors:  Jorge Sánchez-Guerrero; Cynthia Aranow; Meggan Mackay; Bruce Volpe; Betty Diamond
Journal:  Nat Clin Pract Rheumatol       Date:  2008-03

6.  Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier.

Authors:  Sivan Gelb; Ariel D Stock; Shira Anzi; Chaim Putterman; Ayal Ben-Zvi
Journal:  J Autoimmun       Date:  2018-04-04       Impact factor: 7.094

Review 7.  Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons.

Authors:  Eyal Muscal; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 8.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

9.  Transcriptional profiling reveals that C5a alters microRNA in brain endothelial cells.

Authors:  Michael T Eadon; Alexander Jacob; Patrick N Cunningham; Richard J Quigg; Joe G N Garcia; Jessy J Alexander
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

10.  TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice.

Authors:  Jing Wen; Jessica Doerner; Karen Weidenheim; Yumin Xia; Ariel Stock; Jennifer S Michaelson; Kuti Baruch; Aleksandra Deczkowska; Maria Gulinello; Michal Schwartz; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2015-04-22       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.